Glioma Clinical Trial
Official title:
Coping With High Grade Glioma
1. Purpose and Objective:
To determine the feasibility and short- and long-term efficacy of an empirically-based
CST intervention (Keefe et al.) with caregivers of patients with primary malignant
brain cancer.
2. Study Activities and Population Group:
The target sample will be 20 caregiver-patient dyads. Using a randomized controlled,
prospective design, potentially eligible participants will be identified at the time of
initial consultation (see Figure 1). Outcomes will be assessed at baseline,
post-intervention (3 months post-randomization), 6 months post-randomization, and every
4 months up to 2-years in the event that the patient dies.
3. Data Analysis and Risk/Safety Issues:
With only 10 subjects per group we do not have statistical power for direct hypothesis
testing. Nevertheless, p-values will be presented for some analyses (chi-square tests,
t-tests, and Spearman correlations) simply to aid in interpretation of results. In no way
will these p-values be used to declare statistical significance or non-significance of the
test results. Accordingly, the primary focus will be the means, variances, and covariances
of the study endpoints, as well as the change scores in these endpoints across the study
intervention and their 95% confidence limits.
The purpose of this study is to determine the feasibility and short- and long-term efficacy
of an empirically-based CST intervention (Keefe et al.) with caregivers of patients with
primary malignant brain cancer. The target sample will be 20 caregiver-patient dyads. The
caregiver may be a spouse/partner, family member or friend,. Additional inclusion criteria
will include: (1) caregiver provides a weekly minimum of 4 hours of caregiving; (2)
caregiver is 18 years or older; (3) caregiver reading level at or above 8th grade; (4)
caregiver sufficiently fluent in English; (5) the patient shows evidence of problems in
depression, fatigue, sleep disturbance, and/or cognitive impairment as per the treating
neuro-oncologist; (6) the caregiver and patient are willing to be randomized to treatment or
usual care condition; (7) patient is within 3 months of initial diagnosis; (8) patient has
life expectancy of at least 6 months or more; (9) the caregiver is willing to participate in
treatment sessions using a telephone. If a patient dies during the active 12-week study
phase, then the caregiver will be transitioned to the follow-up phase or removed from the
study and, if needed, be referred for appropriate psychiatric or psychological treatment.
Using a randomized controlled, prospective design, potentially eligible participants will be
identified at the time of initial consultation. Outcomes will be assessed at baseline,
post-intervention (3 months post-randomization), 6 months post-randomization, and every 4
months up to 2-years in the event that the patient dies. If the subject is assigned to the
intervention, they will be asked to complete 12 weeks of a coping skills training
intervention. The coping skills intervention will consist of six telephone conversations
during which they will learn strategies to reduce stress. The strategies will include ways
to improve problem solving, communication skills, and managing activities. The subject will
also be asked to complete a packet of questionnaires which will take about 1 hour to do. The
subject will be asked to complete the questionnaires multiple times during the study (before
the coping skills intervention, during the week after the coping skills intervention, and 3
months after the coping skills intervention). If the subject is assigned to the usual care
condition, they will be asked to complete assessments at the same time intervals as
caregivers in the active coping skills intervention. In either condition, in the event that
the patient dies, the caregiver will also be asked to complete assessments every four months
for one year. Patients will be asked to participate in sessions and complete questionnaires
as they are able to.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04539574 -
An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
|
N/A | |
Enrolling by invitation |
NCT04461002 -
Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
|
||
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT03242824 -
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
|
Phase 2 | |
Recruiting |
NCT04186832 -
Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy
|
N/A | |
Completed |
NCT00424554 -
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
|
Phase 2 | |
Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT02805179 -
A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
|
Phase 2 | |
Terminated |
NCT04556929 -
Enhanced Detection in Glioma Excision
|
N/A | |
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Recruiting |
NCT06043232 -
MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
|
||
Not yet recruiting |
NCT06043765 -
Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training
|
N/A | |
Not yet recruiting |
NCT05025969 -
Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
|
||
Completed |
NCT02978261 -
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
|
Phase 1 | |
Completed |
NCT01836536 -
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
|
N/A | |
Terminated |
NCT01502605 -
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
|
Phase 1 | |
Completed |
NCT01479686 -
iMRI Guided Resection in Cerebral Glioma Surgery
|
Phase 3 | |
Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 |